$FRNM News
Last published 1d ago
- 1d agoFRNMFreenome, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoFRNMFreenome Reports Third Quarter 2026 Financial ResultsGlobeNewswire– Third-quarter results reflect revenue of $183.5 million driven by the FDA approval of SimpleScreen™ CRC –
- 3w agoFRNMFreenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC OptionGlobeNewswire– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw – – In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity
- 3w agoFRNMFreenome to Report Third Quarter 2026 Financial Results on November 10, 2026GlobeNewswireBRISBANE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (NASDAQ:FRNM), an early cancer detection company developing blood-based screening tests, today announced that the Company plans to release its
- 1mo agoFRNMFreenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026GlobeNewswire– Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention – – Overall detection of colorectal cancer
- 3mo agoFRNMFDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening TestGlobeNewswireBRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (NASDAQ:FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and Drug Administration
- 3mo agoFRNMABTFDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.GlobeNewswire– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader access to blood-based
- 3mo agoFRNMPCSCFreenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer DetectionGlobeNewswire– Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol "FRNM" on July 21, 2026 – – Gross proceeds to Freenome totaled more than $300 million through a PIPE, led